Breast Cancer
Conditions
Keywords
Breast cancer, Microchimerism, Hematopietic fetal cells
Brief summary
After pregnancy, fetal cells remain in a woman's body for years. These cells may be involved in different physiological situations (e.g. wound healing) and diseases (e.g. cancer).The study will evaluate the level of circulating fetal immune cells in patients with breast cancer vs controls with benign breast tumors, and further characterize these fetal cells. Patients participation will be limited to accepting that an additional blood sample is collected on the day of their preop consultation and blood test.
Detailed description
Breast cancer is the most common cancer in the female population. The protective mechanism associated with pregnancy is not fully understood. During pregnancy fetal cells cross the placental barrier and may remain in the maternal circulation even for up to 30 years after childbirth. This phenomenon is called fetal microchimerism. The presence of circulating fetal cells would have a protective role against breast cancer. However, their phenotype and role in the anti-tumor response is not explored. The objective of the study is to identify the sub-population (s) of circulating fetal immune cells that may have an impact on the processes of carcinogenesis in breast cancer, in the context of fetal microchimerism.
Interventions
OTHERBlood sample
As part of the treatment, 2 EDTA tubes of 10mL will be taken during a scheduled venipuncture as part of the preoperative assessment.
Sponsors
Ruban Rose
Assistance Publique - Hôpitaux de Paris
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 50 Years
Inclusion criteria
* women aged 18-50 * having had a male child * informed and not having objected to participating in the research. Patients: \- having a diagnosis of breast cancer Controls: * operated on for benign breast tumors * cancer free
Exclusion criteria
* autoimmune disease * immunomodulatory treatment * history of cancer other than breast cancer * ongoing hormonal treatment * women not affiliated to the social security * under AME (state medical aid) * under tutorship / curatorship
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentages of fetal cells in each immune cell subpopulation. | 3 years | Using fluorescence activated cell sorting method. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Activation markers. | 3 years | Using immunocytochemistry method. |
| Cytotoxicity markers. | 3 years | Using immunocytochemistry method. |
Countries
France
Outcome results
None listed